FGF9 and melanoma: In this respect, miR-26a was found to antagonize carcinogenesis in the mammary, prostate, pancreas and stomach by targeting the Polycomb group protein EZH2, myeloid cell leukemia 1 (Mcl-1) or metadherin, cyclin E2, and fibroblast growth factor 9 (FGF9), respectively [11–16]; miR-26a suppression of melanoma, prostate and liver cancers was also attributed to its role in enhancing miRNA biogenesis by targeting Lin28B and Zcchc11 [17].